Consolidated Statement Of Cash Flows

Astellas Pharma Inc. - Filing #7258550

Concept 2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
As at
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
As at
2023-03-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss)
50,747,000,000 JPY
JPY
JPY
50,747,000,000 JPY
JPY
50,747,000,000 JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
17,045,000,000 JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
17,045,000,000 JPY
17,045,000,000 JPY
JPY
JPY
Impairment losses (reversal of impairment losses)
187,564,000,000 JPY
78,931,000,000 JPY
Decrease (increase) in inventories
-50,225,000,000 JPY
-60,036,000,000 JPY
Other
18,622,000,000 JPY
34,816,000,000 JPY
Subtotal
279,989,000,000 JPY
210,587,000,000 JPY
Income taxes paid
-85,478,000,000 JPY
-38,112,000,000 JPY
Net cash provided by (used in) operating activities
194,512,000,000 JPY
172,475,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-37,003,000,000 JPY
-38,056,000,000 JPY
Purchase of intangible assets
-20,327,000,000 JPY
-44,441,000,000 JPY
Payments for acquisition of subsidiaries
JPY
-784,974,000,000 JPY
Other
-53,269,000,000 JPY
1,816,000,000 JPY
Net cash provided by (used in) investing activities
-89,419,000,000 JPY
-845,802,000,000 JPY
Cash flows from financing activities
Purchase of treasury shares
-6,960,000,000 JPY
-10,735,000,000 JPY
Other
-23,814,000,000 JPY
-16,539,000,000 JPY
Net cash provided by (used in) financing activities
-261,367,000,000 JPY
614,060,000,000 JPY
Cash and cash equivalents
188,372,000,000 JPY
335,687,000,000 JPY
376,840,000,000 JPY
Effect of exchange rate changes on cash and cash equivalents
8,960,000,000 JPY
18,113,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.